JP6872805B2 - 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用 - Google Patents

奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用 Download PDF

Info

Publication number
JP6872805B2
JP6872805B2 JP2018564968A JP2018564968A JP6872805B2 JP 6872805 B2 JP6872805 B2 JP 6872805B2 JP 2018564968 A JP2018564968 A JP 2018564968A JP 2018564968 A JP2018564968 A JP 2018564968A JP 6872805 B2 JP6872805 B2 JP 6872805B2
Authority
JP
Japan
Prior art keywords
day
compound
aβo
treatment
herb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018564968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518034A5 (enExample
JP2019518034A (ja
Inventor
ユホン ドン
ユホン ドン
チュン‐ション チャン
チュン‐ション チャン
シェンタン リン
シェンタン リン
Original Assignee
サンレーゲン ヘルスケア アーゲー
サンレーゲン ヘルスケア アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンレーゲン ヘルスケア アーゲー, サンレーゲン ヘルスケア アーゲー filed Critical サンレーゲン ヘルスケア アーゲー
Publication of JP2019518034A publication Critical patent/JP2019518034A/ja
Publication of JP2019518034A5 publication Critical patent/JP2019518034A5/ja
Priority to JP2021067485A priority Critical patent/JP2021113204A/ja
Application granted granted Critical
Publication of JP6872805B2 publication Critical patent/JP6872805B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2018564968A 2016-06-08 2017-06-06 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用 Active JP6872805B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021067485A JP2021113204A (ja) 2016-06-08 2021-04-13 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662347103P 2016-06-08 2016-06-08
US62/347,103 2016-06-08
PCT/CN2017/087341 WO2017211274A1 (en) 2016-06-08 2017-06-06 Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021067485A Division JP2021113204A (ja) 2016-06-08 2021-04-13 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用

Publications (3)

Publication Number Publication Date
JP2019518034A JP2019518034A (ja) 2019-06-27
JP2019518034A5 JP2019518034A5 (enExample) 2020-01-16
JP6872805B2 true JP6872805B2 (ja) 2021-05-19

Family

ID=60577583

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018564968A Active JP6872805B2 (ja) 2016-06-08 2017-06-06 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用
JP2021067485A Pending JP2021113204A (ja) 2016-06-08 2021-04-13 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021067485A Pending JP2021113204A (ja) 2016-06-08 2021-04-13 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用

Country Status (12)

Country Link
US (2) US11406616B2 (enExample)
EP (1) EP3468551A4 (enExample)
JP (2) JP6872805B2 (enExample)
KR (1) KR20190017873A (enExample)
CN (2) CN110300581B (enExample)
AU (1) AU2017277005B2 (enExample)
CL (1) CL2018003537A1 (enExample)
MX (1) MX2018015188A (enExample)
NZ (1) NZ749389A (enExample)
SG (1) SG11201810580PA (enExample)
TW (1) TWI749016B (enExample)
WO (1) WO2017211274A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004023A2 (pt) * 2017-09-12 2020-09-08 Sunregen Healthcare Ag uso de um composto e composição farmacêutica ou suplemento nutricional
CN111773351A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及姜黄组合物在制备降血糖及降血压的药物组合物中的应用
CN111773274A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及车前子组合物在制备降血糖及降血压的药物组合物中的应用
JP7685134B2 (ja) * 2019-11-27 2025-05-29 リファインホールディングス株式会社 インスリン分泌促進剤並びにこれを用いた血糖値改善剤、糖尿病改善剤及び食品
JP2024523429A (ja) * 2021-06-18 2024-06-28 サンレーゲン ヘルスケア エージー ウイルス感染の神経学的合併症の処置と予防のための新規化合物
JP2023061448A (ja) * 2021-10-20 2023-05-02 リファインホールディングス株式会社 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
JPWO2024075625A1 (enExample) * 2022-10-02 2024-04-11

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS558351A (en) 1978-07-05 1980-01-21 Hitachi Ltd Press machine
DE3032300A1 (de) 1980-08-27 1982-04-01 Alfred Ing. Wien Lohninger Mittel zur parenteralen ernaehrung
JPS5919775U (ja) 1982-07-26 1984-02-06 ワイケイケイ株式会社 カ−テンウオ−ルの断熱窓
JPH02247125A (ja) * 1989-03-17 1990-10-02 Koken Kk 悪性腫瘍細胞増殖抑制剤
JP3558351B2 (ja) 1992-12-07 2004-08-25 邦郎 辻 免疫抑制剤
DE19821003A1 (de) * 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20020006959A1 (en) 2000-05-01 2002-01-17 Henderson Samuel T. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism
EP1289530B1 (en) 2000-06-14 2006-10-04 PORTER, William Leslie Lipids for modulating immune response
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
EP1900364B1 (en) 2001-04-18 2013-09-25 ProMetic BioSciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
CN1764446A (zh) * 2003-03-13 2006-04-26 康福玛医药公司 含有长链和中链甘油三酯的药物制剂
WO2004103307A2 (en) 2003-05-20 2004-12-02 Baylor Research Institute Method of use of five and fifteen carbon fatty acids
JP4334956B2 (ja) 2003-09-18 2009-09-30 株式会社ノエビア 細胞賦活剤、美白剤、及び抗酸化剤
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
WO2008039855A2 (en) 2006-09-26 2008-04-03 Baylor Research Institute Nutrient sensor
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
KR100829729B1 (ko) * 2007-01-29 2008-05-15 한불화장품주식회사 병이소초 추출물을 주요 활성성분으로 함유하는 피부외용제 조성물
AU2008318196B2 (en) 2007-11-02 2014-04-10 Prometic Pharma Smt Limited Medium-chain length fatty acids and glycerides as nephroprotection agents
DE102008046227A1 (de) * 2008-06-10 2009-12-17 Ludwig-Maximilians-Universität München Hochdurchsatzmethode zur Analyse der Fettsäurezusammensetzung in Plasmaphosphoglyceriden
DE102008057867A1 (de) 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
CN101879156B (zh) 2009-05-07 2013-01-30 上海医药工业研究院 一种药物组合物及其应用
MX348036B (es) 2009-12-30 2017-05-24 Baylor Res Institute Terapia anaplerótica para la enfermedad de alzheimer y el cerebro envejecido.
SG182414A1 (en) * 2010-01-08 2012-08-30 Catabasis Pharmaceuticals Inc Fatty acid fumarate derivatives and their uses
MY173496A (en) * 2010-02-10 2020-01-29 Oryza Oil & Fat Chemical Co Ltd Age production inhibitor
US20110301238A1 (en) 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
US20110306663A1 (en) 2010-06-14 2011-12-15 Baylor Research Institute Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
EP2407155B1 (en) * 2010-07-15 2012-12-26 Hybrigenics S.A. Formulations of inecalcitol
CN107028926A (zh) * 2011-08-26 2017-08-11 国立大学法人大阪大学 糖尿病性心血管并发症的预防/治疗剂
CN102526643B (zh) * 2012-03-22 2013-09-11 常熟市虞山绿茶有限公司 一种治疗口腔溃疡的中草药含片
BR112015013349A2 (pt) 2012-12-13 2017-07-11 Baylor Res Institute At Dallas trieptanoína para o tratamento de deficiência de transportador de glicose 1
JP6963895B2 (ja) * 2013-08-02 2021-11-10 シュバイツァー モウドゥイ インターナショナル インコーポレイテッド 再構成植物原料を含む食用製品
CA2929601A1 (en) * 2013-11-14 2015-05-21 Karin Borges Neurodegenerative disorders and methods of treatment and diagnosis thereof
CN103641713B (zh) * 2013-11-15 2015-10-21 浙江大学 甘油单酯衍生物的制备方法及应用
WO2015110977A1 (en) 2014-01-22 2015-07-30 Rolexi Marketing (Pty) Ltd Fatty acid composition and medicinal use thereof
CN104286296A (zh) * 2014-09-25 2015-01-21 王美华 一种凉茶
JP6406978B2 (ja) 2014-11-04 2018-10-17 株式会社シー・アクト 脂肪酸混合物
CN105267501A (zh) * 2015-11-04 2016-01-27 夏茂森 一种治疗毒蛇咬伤的中药组合物
CN105381182A (zh) * 2015-11-20 2016-03-09 冯天寿 一种治疗慢性荨麻疹的中药及其应用
CA3004996A1 (en) 2015-12-04 2017-06-08 Nestec S.A. Method for improving cognition

Also Published As

Publication number Publication date
CN110300581B (zh) 2023-09-08
CL2018003537A1 (es) 2019-05-03
MX2018015188A (es) 2019-08-21
JP2021113204A (ja) 2021-08-05
EP3468551A4 (en) 2020-01-22
US11406616B2 (en) 2022-08-09
KR20190017873A (ko) 2019-02-20
NZ749389A (en) 2022-12-23
CA3026152A1 (en) 2017-12-14
CN117298092A (zh) 2023-12-29
AU2017277005B2 (en) 2022-12-22
CN110300581A (zh) 2019-10-01
TW201801720A (zh) 2018-01-16
EP3468551A1 (en) 2019-04-17
WO2017211274A1 (en) 2017-12-14
JP2019518034A (ja) 2019-06-27
AU2017277005A1 (en) 2019-01-17
US20220362197A1 (en) 2022-11-17
TWI749016B (zh) 2021-12-11
US20190255129A1 (en) 2019-08-22
SG11201810580PA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
JP6872805B2 (ja) 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用
JP5816171B2 (ja) 神経変性障害における脳の健康を保護するための化合物、組成物および方法
Malek et al. Bronchodilatory effect of Portulaca oleracea in airways of asthmatic patients
EP3197445B1 (en) Proline or proline derivatives for the treatment of dementia
WO2023034115A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
WO2018113027A1 (zh) 白果内酯作为增效剂在制备防治脑神经损伤性疾病药物的应用
WO2022251116A1 (en) Modified herbal compositions for neuromodulation
CA3026152C (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
BR112020004023A2 (pt) uso de um composto e composição farmacêutica ou suplemento nutricional
JP5176127B2 (ja) 視覚機能障害の予防または改善剤
CN110151833A (zh) 一种治疗阿尔兹海默症的药物组合物
RS65663B1 (sr) Acetil leucin za upotrebu u lečenju sindroma nemirnih nogu
US20090022757A1 (en) Method for treating photoreceptor cell degeneration
CN103908567B (zh) 一种用于治疗糖尿病痛性神经病变的复方制剂及其应用
HK40021759A (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
JP5417727B2 (ja) 網膜保護剤
HK40021759B (zh) 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
WO2022241707A1 (en) Curcuminoid-rich oil extract, its preparation method and uses for treating diseases associated with neuron injury
JP5162859B2 (ja) 眼精疲労の予防又は緩和剤
WO2025194157A2 (en) Therapeutic combinations for mitochondrial and other disorders
TW202103679A (zh) 一種落葵萃取物用於製備預防或治療神經系統疾病組合物的用途
CN120459095A (zh) 氨基吡啶类物质抑制α-突触核蛋白聚集和路易小体形成的用途
US20180055901A1 (en) Regulation of Brain Biogenic Amines Associated with Depression by a Formulation from Botanical Source
WO2006090557A1 (ja) サルビアノール酸b等を主成分とする脳卒中又は脳卒中後遺症の予防用又は治療用薬剤
DE102006040278A1 (de) Arzneimittel zur Behandlung des Charles-Bonnet-Syndroms

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210413

R150 Certificate of patent or registration of utility model

Ref document number: 6872805

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250